BICAVERA GLUCOSA 2.3%, Calcium 1.75 mmol/l SOLUTION FOR PERITONEAL DIALYSIS
How to use BICAVERA GLUCOSA 2.3%, Calcium 1.75 mmol/l SOLUTION FOR PERITONEAL DIALYSIS
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
bicaVera Glucose 2.3%, Calcium 1.75 mmol/lsolution for peritoneal dialysis
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is bicaVera and what is it used for
- What you need to know before you use bicaVera
- How to use bicaVera
- Possible side effects
- Storage of bicaVera
- Contents of the pack and other information
1. What is bicaVera and what is it used for
bicaVera is used to clean the blood via the peritoneum in patients with chronic renal failure in the terminal phase. The type of blood cleansing is known as peritoneal dialysis.
2. What you need to know before you use bicaVera
Do not use bicaVera Glucose 2.3%, Calcium 1.75 mmol/l
- if your blood potassium level is too low
- if your blood calcium level is too high
- if your body fluid volume is too low
- if your blood pressure is low
Peritoneal dialysis should not be started if you have
- abdominal region disorders such as
- wounds, or after surgery
- severe burns
- extensive skin inflammatory reactions
- peritonitis
- uncured suppurating wounds
- umbilical, inguinal, or diaphragmatic hernias
- tumors in the abdomen or intestine
- inflammatory bowel diseases
- intestinal obstruction
- pulmonary disease, especially pneumonia
- generalized blood infection caused by bacteria
- very high levels of fat in the blood
- accumulation of toxins from urine in the blood, which cannot be eliminated by peritoneal dialysis
- malnutrition and severe weight loss, especially when adequate protein nutrition is not possible
Warnings and precautions
Consult your doctor immediately:
- in case of severe loss of electrolytes (salts)caused by vomiting and/or diarrhea
- in case of peritonitis, recognizable by cloudy dialysate draining from your peritoneum, abdominal pain, fever, malaise, or, in very rare cases, blood infection.
Please show your doctor the bag containing the drained dialysate.
- in case of severe abdominal pain, abdominal distension, or vomiting. This may be a sign of encapsulating peritoneal sclerosis, a complication of peritoneal dialysis treatment that can be life-threatening.
Peritoneal dialysis may cause loss of proteinsand water-soluble vitamins. It is recommended to follow a suitable diet or take nutritional supplements to avoid deficiency states.
Your doctor should check the balance of electrolytes (salts), blood cell count, kidney function, body weight, and nutritional status.
Using bicaVera with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Peritoneal dialysis may alter the effect of some medicines, so it may be necessary for your doctor to change the dose for some of them, especially the following:
- Medicines for heart failure, such as digoxin.
Your doctor will determine your blood potassium level and, if necessary, take appropriate measures.
- Medicines that affect calcium levels, such as those containing calcium or vitamin D.
- Medicines that increase urine excretion, such as diuretics.
- Insulin or medicinestaken orally and that lower blood sugar levels. Your blood sugar level should be checked regularly.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine.
There is no sufficient data on the use of bicaVera in pregnant or breastfeeding women. If you are pregnant or breastfeeding, you should only use bicaVera if your doctor considers it absolutely necessary.
Driving and using machines
bicaVera has no or negligible influence on the ability to drive and use machines.
3. How to use bicaVera
Follow exactly the administration instructions for this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
Your doctor will determine the method, duration, and frequency of use, as well as the required volume of solution and the dwell time in the peritoneal cavity.
If you have tension in the abdominal region, your doctor may reduce the volume.
Continuous Ambulatory Peritoneal Dialysis (CAPD)
- Adults:The usual dose is between 2000 - 2500 ml of solution four times a day, depending on body weight and renal function.
The solution is drained after a dwell time of between 2 and 10 hours.
- Children:The doctor will determine the required volume of dialysis solution depending on tolerance, age, and body surface area of the child.
The recommended initial dose is 600 - 800 ml/m2 of body surface area four times a day (up to 1000 ml/m2 at night).
Automated Peritoneal Dialysis (APD)
For this type of dialysis, the sleep-safesystem is used. The exchange of bags is controlled automatically by the cycler during the night.
- Adults:The normal prescription is 2000 ml (maximum 3000 ml) per exchange with 3-10 exchanges during the night and the cycler time of 8 to 10 hours, and one or two exchanges during the day.
- Children:The volume per exchange should be 800-1000 ml/m2 (up to 1400 ml/m2) of body surface area with 5-10 exchanges during the night.
Use bicaVera only in the peritoneal cavity.
Use only bicaVera if the solution is clear and the bag is not damaged.
bicaVera is available in a double-chamber bag. Before using it, mix the solutions from the two chambers as described.
Instructions for use:
For using the staysafesystem for Continuous Ambulatory Peritoneal Dialysis (CAPD)
First, heat the bag with the solution to body temperature. This should be done using a suitable heating plate. The heating time depends on the volume of the bag and the bag warmer used (for a 2000 ml bag at an initial temperature of 22°C, it will take approximately 120 minutes). You can obtain more detailed information in the instruction manual of your warmer. Do not use a microwave oven to heat the solution due to the risk of local overheating. The exchange of bags can be carried out after heating the solution.
- Preparation of the solution
? Check the heated solution bag (label, expiration date, transparency of the solution, integrity of the bag and overbag, integrity of the weld) ? Place the bag on a solid surface. ? Open the overbag of the bag and the package of the disinfection plug/closure plug. ? Wash your hands using an antimicrobial hand wash lotion. ? Roll up the bag, which is placed horizontally on the overbag, from one of the lateral edges until the intermediate weld opens. The solutions from the two chambers mix automatically. ? Then roll up the bag from the top edge until the weld of the lower triangle opens completely. ? Check that all welds are completely open. ? Check that the solution is clear and that the bag has no leaks.
- Preparation of the bag exchange
? Hang the solution bag on the upper hanger of the infusion stand, unroll the tubes of the solution bag, and place the DISC connector in the organizer. After unrolling the tubes of the drainage bag, hang the drainage bag on the lower hanger of the infusion stand ? Place the catheter connector in one of the two connections of the organizer ? Put the new disinfection plug/closure plug in the other free connection. ? Disinfect your hands and remove the protective cap from the DISC connector. ? Connect the catheter adapter to the DISC.
- Outflow
? Open the extension valve. The outflow starts. ? Position ?
- Purge
? Once the outflow is complete, purge new solution to the drainage bag (approximately 5 seconds). ? Position ??
- Inflow
? Start the inflow by turning the switch to ? Position ???
- Safety phase
? Automatic closure of the catheter extension with the PIN ? Position ????
- Disconnection
? Remove the protective cap from the new disinfection plug/closure plug and screw it into the old one. ? Unscrew the catheter connector from the DISC connector and screw the catheter connector into the new disinfection plug/closure plug.
- Closing the DISC
? Close the DISC with the open end of the protective cap, which has remained in the other insert of the organizer.
- Check the transparency and weight of the drained dialysate and if the effluent is clear discard it.
For using the sleepsafesystem for Automated Peritoneal Dialysis (APD)
For starting the sleep-safesystem, consult your instruction manual.
.
sleepsafesystem of 3000 ml
- Preparation of the solution: see stay-safesystem
- Unroll the tube of the bag
- Remove the protective cap
- Place the connector in the free port of the cycler tray
- The bag is now ready to use with the sleep-safeequipment
sleep-safesystem of 5000
- Preparation of the solution
? Check the solution bag (label, expiration date, transparency of the solution, integrity of the bag and overbag, integrity of the weld) ? Place the bag on a solid surface. ? Open the overbag of the bag. ? Wash your hands using an antimicrobial hand wash solution. ? Unfold the intermediate weld and the bag connector.
? Roll up the bag, which is placed horizontally on the overbag, from the diagonal end to the bag connector. The intermediate weld will open. ? Continue until the weld of the small chamber also opens. ? Check that all welds are completely open. ? Check that the solution is clear and that the bag has no leaks.
2 - 5.: see sleep-safesystem 3000 ml.
The bags are for single use and any unused solution should be discarded.
After proper training, bicaVera can be used independently at home. Make sure to follow all the steps you have learned during training and maintain proper hygiene conditions when exchanging bags.
Always check the turbidity of the drained dialysate. See section 2 "Warnings and precautions"
If you use more bicaVera than you should
If you infuse an excess of dialysis solution into the peritoneal cavity, it can be drained. If you use too many bags, contact your doctor, as it may cause electrolyte and/or fluid imbalance.
If you forget to use bicaVera
Try to reach the total prescribed volume for 24 hours to avoid consequences that may endanger your life. Check with your doctor if you are unsure.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You may experience the following side effects as a result of peritoneal dialysis treatment in general:
very common(may affect more than 1 in 10 people):
- peritonitis, which is noticeable by cloudy dialysate draining from your peritoneum, abdominal pain, fever, malaise, or, in very rare cases, blood infection.
Please show your doctor the bag containing the drained dialysate.
- skin inflammation at the catheter exit site or along the length of the catheter, recognizable by redness, swelling, pain, discharge, or crusts.
- hernia in the abdominal wall.
Contact your doctor immediately if you experience any of these side effects.
Other side effects of the treatment are the following:
common(may affect up to 1 in 10 people):
- problems with the inflow or outflow of dialysate
- feeling of stretching or fullness of the abdomen
- shoulder pain
uncommon(may affect up to 1 in 100 people):
- diarrhea
- constipation
frequency not known(cannot be estimated from the available data)
- breathing difficulties due to elevation of the diaphragm
- encapsulating peritoneal sclerosis, whose symptoms could be abdominal pain, abdominal distension, or vomiting
You may experience the following side effects when using bicaVera:
very common(may affect more than 1 in 10 people):
- potassium deficiency
common(may affect up to 1 in 10 people):
- high blood sugar levels
- high levels of fat in the blood
- weight gain
uncommon(may affect up to 1 in 100 people):
- excess calcium if calcium intake is too high
- body fluid volume too low, which can be recognized by rapid weight loss,
- low blood pressure,
- rapid pulse
- body fluid volume too high, which can be recognized by rapid weight gain
- fluid in the tissues and lungs,
- high blood pressure,
- breathing difficulties
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of bicaVera
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bag and carton after EXP. The expiry date is the last day of the month shown.
Do not store below 4°C.
The ready-to-use solution should be used immediately, within a maximum of 24 hours after mixing.
Do not use this medicine if the solution is not clear or if the bag is damaged.
6. Container Content and Additional Information
bicaVera Composition
The active ingredients in one liter of ready-to-use solution are
Calcium Chloride Dihydrate | 0.2573 g |
Sodium Chloride | 5.786 g |
Sodium Bicarbonate | 2.940 g |
Magnesium Chloride Hexahydrate | 0.1017 g |
Glucose Monohydrate (equivalent to 22.73 g of glucose) | 25 g |
These amounts of active substance are equivalent to:
1.75 mmol/l calcium, 134 mmol/l sodium, 0.5 mmol/l magnesium, 104.5 mmol/l chloride, 34 mmol/l bicarbonate, and 126.1 mmol/l glucose.
The other components of bicaVera are water for injectable preparations, hydrochloric acid, sodium hydroxide, and carbon dioxide.
Product Appearance and Container Content
The solution is transparent and colorless.
The theoretical osmolarity of the ready-to-use solution is 401 mOsm/l, and the pH is approximately 7.40.
bicaVera is available in a double-chamber bag. One chamber contains the alkaline solution of sodium bicarbonate, and the other chamber contains the acidic solution with glucose and electrolytes in a 1:1 ratio.
bicaVera is available in the following application systems and container sizes:
stay•safe: 4 bags of 2000 ml 4 bags of 2500 ml 4 bags of 3000 ml | sleep•safe: 4 bags of 2000 ml 4 bags of 2500 ml 4 bags of 3000 ml 2 bags of 5000 ml |
Only some container sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Fresenius Medical Care Deutschland GmbH,
Else-Kröner-Straße 1, 61352 Bad Homburg v.d.H.,
Germany
Manufacturer
Fresenius Medical Care Deutschland GmbH,
Frankfurter Straße 6-8, 66606 St. Wendel,
Germany
Local Representative
Fresenius Medical Care España S.A.
C/ Ronda de Poniente, 8, planta baja, Parque Empresarial Euronova,
28760 Tres Cantos (Madrid)
This medicinal product is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
See the end of this multilingual prospectus.
Date of the last revision of this prospectus: 11/2023
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
This medicinal product is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
DE, AT, BE: bicaVera 2.3 % Glucose, 1.75 mmol/l Calcium, Peritoneal dialysis solution
DK: bicaVera 2.3% glucose, 1.75 mmol/l calcium, Peritoneal dialysis fluid
EL, CY: bicaVera 2.3% γλυκ?ζη, 1.75 mmol/l ασβ?στιο, Περιτονα?κ?ς διαπ?δυσης (κ?θαρσης) λ?ση
ES: bicaVera Glucosa 2.3% Calcio 1.75 mmol/lsolution for peritoneal dialysis
FI: bicaVera 2.3 % glukoosi, 1.75 mmol/l kalsium, peritonealidialyysineste
FR, BE, LU: bicaVera 2.3 % glucose, 1.75 mmol/l calcium, solution for peritoneal dialysis
IT: bicaVera 2.3 % Glucosio, 1.75 mmol/l Calcio, Soluzione per dialisi peritoneale
NL, BE: bicaVera 2.3 % glucose, 1.75 mmol/l calcium, oplossing voor peritoneale dialyse
NO: bicaVera 2.3 % glukose, 1.75 mmol/l kalsium, peritonealdialysevæske
PT: bicaVera 2.3% Glucose 1.75 mmol/l Cálcio, Solução para diálise peritoneal
SE: bicaVera 2.3% Glucose, 1.75 mmol/l Calcium, peritonealdialysvätska
UK(XI): bicaVera 2.3 % Glucose, 1.75 mmol/l Calcium, Solution for peritoneal dialysis
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to BICAVERA GLUCOSA 2.3%, Calcium 1.75 mmol/l SOLUTION FOR PERITONEAL DIALYSISDosage form: PERITONEAL DIALYSIS, 1000 mlActive substance:Manufacturer: Fresenius Medical Care Deutschland GmbhPrescription requiredDosage form: PERITONEAL DIALYSIS, 4.25 %Active substance:Manufacturer: Fresenius Medical Care Deutschland GmbhPrescription requiredDosage form: PERITONEAL DIALYSISActive substance:Manufacturer: Fresenius Medical Care Deutschland GmbhPrescription required
Online doctors for BICAVERA GLUCOSA 2.3%, Calcium 1.75 mmol/l SOLUTION FOR PERITONEAL DIALYSIS
Discuss questions about BICAVERA GLUCOSA 2.3%, Calcium 1.75 mmol/l SOLUTION FOR PERITONEAL DIALYSIS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
